Canagliflozin 100 mg

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Diabetes Mellitus, Type 2

LLYHuman Insulin Inhalation Powder

Phase 3

NVOInsulin Icodec

Phase 3

NVOInsulin Glargine 100U/mL

Phase 3

LLYDetemir

Phase 3

LLYInsulin lispro mix 25

Phase 3

View Full Landscape

Drug Information

Target Indication

Diabetes Mellitus, Type 2

Clinical Trial

NCT01106651

Last updated: 5/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

Tapentadol (CG5503) Extended Release (ER)Phase 3

Pain

Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preFPhase 3

Respiratory Syncytial Viruses

D/C/F/TAFPhase 3

Human Immunodeficiency Virus Type 1

NesiritidePhase 3

Heart Decompensation

Fumaric Acid EstersPhase 3

Psoriasis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts